Every Form 4 that Theriva Biologics, Inc. (TOVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOVX filings page.
Theriva Biologics, Inc. reported an equity award to its senior leadership. On 01/05/2026, a reporting person who serves as director, CEO and CFO received an option grant over 475,000 shares of common stock at an exercise price of $0.241 per share.
The stock options become exercisable on a pro rata monthly basis over 36 months, starting on 02/01/2026, and are scheduled to expire on 01/04/2033 if not exercised. Following this grant, the reporting person held 475,000 derivative securities directly, aligning a portion of their compensation with the company’s future share performance.
Theriva Biologics, Inc. director John J. Monahan reported a new stock option grant. On 01/05/2026 he received stock options to buy 75,000 shares of common stock at an exercise price of $0.241 per share. The options become exercisable starting 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, which means a portion of the options becomes available to exercise each month during the first year.
Theriva Biologics, Inc. reported an insider equity award to one of its directors. The Form 4 shows a grant of 75,000 stock options with an exercise price of $0.241 per share on 01/05/2026. These options become exercisable starting 02/01/2026 and expire on 01/04/2033. According to the footnote, the options vest on a pro rata monthly basis over 12 months, meaning the director earns a portion of the grant each month during the first year.
Theriva Biologics, Inc. reported a new equity award to one of its directors. On 01/05/2026, the director received 75,000 stock options to purchase common stock at an exercise price of $0.241 per share. These options are classified as derivative securities and are held directly by the reporting person.
The options begin to vest on 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, meaning the award is spread evenly across a one-year period. Following this grant, the reporting person beneficially owns 75,000 derivative securities linked to Theriva Biologics common stock.